GP6 and autoimmune thrombocytopenic purpura: In conclusion, our data suggest that eltrombopag, through its role in up-regulation of GPVI receptor expression and increase soluble GPVI levels, might reduce bleeding manifestations, decrease bleeding score and improve the quality of life of chronic and persistent ITP children independent of its effect on platelet count suggesting the possible role of eltrombopag in enhancing platelet function.